|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Measur- ing antiplatelet drug effects in the laboratory显示文摘 | Harrison P Frelinger AL 3rd FurmanMI | 2007 | Thromb Res2007，120，3： | 1 |
| 2 | Current options in platelet function testing显示文摘 | Miehelson AD Frelinger AL 3rd Furman MI | 2006 | Am J Cardio 12006，98，10： | 1 |
| 3 | Measuring antiplateletdrug effects in the laboratory显示文摘 | Harrison P Frelinger AL 3rd Furman MI eta 1 | 2007 | Thromb Res2007，120，： | 1 |
| 4 | Current options in platelet function testing显示文摘 | Michelson AD Frelinger AL 3rd Furman MI | 2006 | Am J Cardiol2006，98，10： | 1 |
| 5 | Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclo- oxygenase-l-and cyclooxygenase-2-independent path- way : a 700-patient study of aspirin resistance 显示文摘 | Frelinger AL 3rd Furman MI Linden MD | 2006 | Circulation2006，113，25： | 1 |
| 6 | Residual arachidonic acid-induced platelet activation via an adenosine diphosphatedependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance显示文摘 | Frelinger AL 3rd Furman MI Linden MD | 2006 | Circulation2006，113，25： | 1 |
| 7 | Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PEN1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function显示文摘 | Frelinger AL 3rd Bhatt DL Lee RD | 2013 | J Am Coil Cardiol2013，61，8： | 1 |
| 8 | Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease显示文摘 | Mega JL Hochholzer W Frelinger AL 3rd | | 0，，： | 1 |
| 9 | A randomized, 2- period, crossover design study to assess the effects ofdexiansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel iu healthy volunteers 显示文摘 | Frelinger AL 3rd Lee RD Mulford DJ | 2012 | J Am Coll Cardiol2012，59，： | 1 |
| 10 | Dosing clopidogrel based on CYP 2 C 19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease 显示文摘 | MEGA JL HOCHHOLZER W FRELINGER AL 3rd | 2011 | JAMA2011，306，20： | 1 |
| 11 | Application of flow cytometry to platelet disorders 显示文摘 | Linden MD Frelinger AL 3rd Barnard MR | 2004 | Semin Thromb Hemost2004，30，5： | 1 |
| 12 | Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease 显示文摘 | Mega JL Hochholzer W Frelinger AL 3rd | 2011 | J Am Med Assoc2011，306，20： | 1 |
| 13 | Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease 显示文摘 | Mega JL Hochholzer W Frelinger AL 3rd | 2011 | JAMA2011，306，： | 1 |
| 14 | Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms(CYP2C19,ABCB1,PON1),noncompliance,diet,smoking,co-medications(including proton pump inhibitors),and pre-existent variability in platelet function显示文摘 | Frelinger AL 3rd Bhatt DL Lee RD | 2013 | J Am Coll Cardiol2013，61，8： | 1 |
| 15 | Current options in platelet function testing显示文摘 | Michelson AD Frelinger AL 3rd Furman MI | 2006 | Am J Cardio12006，98，10： | 1 |
| 16 | Dosing clopi- dogrel based on CYP2C19 genotype and the effect on platelet re- activity in patients with stable cardiovascular disease显示文摘 | Mega JL Hochholzer W Frelinger AL 3rd | 2011 | JAMA2011，306，20： | 1 |
| 17 | Measur- ing antiplatelet drug effects in the laboratory 显示文摘 | Harrison P Frelinger AL 3rd Furman MI | 2007 | Thrombo Res2007，120，3： | 1 |
| 18 | Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease 显示文摘 | Mega JL Hoehholzer W Frelinger AL 3rd | 2011 | lAMA2011，306，20： | 1 |
| 19 | Dosing clopidogrel based on CYP2C19 genotype and the effect on plateIet reactivity in patients with stable cardiovascular disease显示文摘 | Mega JL Hochholzer W Frelinger AL 3rd | 2011 | JAMA2011，306，20： | 1 |
| 20 | Measuring antiplatelet drug effects in the laboratory 显示文摘 | Harrison P Frelinger AL 3rd Furman MI | 2007 | Thromb Res2007，120，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员